By Colin Kellaher
Merck & Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its blockbuster cancer drug Keytruda in an aggressive type of breast cancer that has an increased risk for recurrence.
The Kenilworth, N.J., drugmaker said the approval covers Keytruda for the treatment of patients with high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.
Merck said Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is now approved for 30 indications in the U.S.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires